Gregory Scott Day
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory Scott Day has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Brian Andrew Gordon
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
22 shared publications - Randall J. Bateman
Washington University School of Medicine, St. Louis, MO
21 shared publications John C. Morris
Department of Neurology Washington University in St. Louis St. Louis MO USA
19 shared publications- Tammie Lee Smith Benzinger
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
16 shared publications - Clifford R. Jack
Department of Radiology, Mayo Clinic, Rochester, MN; and
15 shared publications - Neill R. Graff-Radford
Department of Neurology, Mayo Clinic, Jacksonville, FL; and
15 shared publications
Latest Publications
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 5 (4)
Education Research: Strengthening the Neurology Pipeline
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 5 (4)
Education Research: Strengthening the Neurology Pipeline
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (6) , e200658
Geographic Variation in Diagnostic Codes Associated With Mild Cognitive Impairment, Alzheimer Disease, and Related Dementias
Background and ObjectivesMild cognitive impairment (MCI), Alzheimer disease (AD), and AD-related dementias (ADRD) are growing public health concerns. Regional, demographic, and clinical differences...
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (6) , e200658
Geographic Variation in Diagnostic Codes Associated With Mild Cognitive Impairment, Alzheimer Disease, and Related Dementias
Background and ObjectivesMild cognitive impairment (MCI), Alzheimer disease (AD), and AD-related dementias (ADRD) are growing public health concerns. Regional, demographic, and clinical differences...
- Open Access
A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes
Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.
Open AccessA shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes
Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease
Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18 F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n = 390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease
Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18 F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n = 390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.
- Open Access
- 3 November 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases
Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of paraclinical parameters compared in discovery and validation cohorts. CSF GAD65‐antibody titers ≥ 1 nmol/L performed best in discovery (AUC 0.956) and validation (AUC 0.949; p = 0.814), with 89.7% sensitivity and 94% specificity for identifying tGAD65. Serum titers > 20 nmol/L and indices of intrathecal synthesis showed lower discriminative ability. Our finding aims to reduce misdiagnosis and identify potential immunotherapy‐responsive diseases.
- 3 November 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessCerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases
Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of paraclinical parameters compared in discovery and validation cohorts. CSF GAD65‐antibody titers ≥ 1 nmol/L performed best in discovery (AUC 0.956) and validation (AUC 0.949; p = 0.814), with 89.7% sensitivity and 94% specificity for identifying tGAD65. Serum titers > 20 nmol/L and indices of intrathecal synthesis showed lower discriminative ability. Our finding aims to reduce misdiagnosis and identify potential immunotherapy‐responsive diseases.
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218591
Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218591
Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...
- Open Access
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218519
EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease
Background and ObjectivesEarly-onset Alzheimer disease (EOAD) is associated with substantial variability in clinical progression, and reliable biomarkers to predict the transition from mild cogniti...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218519
Open AccessEOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease
Background and ObjectivesEarly-onset Alzheimer disease (EOAD) is associated with substantial variability in clinical progression, and reliable biomarkers to predict the transition from mild cogniti...
- 5 October 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 143, 92-98
Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort
- 5 October 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 143, 92-98
Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort
- Open Access
- 1 October 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (4)
Plasma biomarker signatures in patients with rapidly progressive dementia
INTRODUCTION: Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS: Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS: Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p‐tau)217 and p‐tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment–non‐responsive causes of RPD. DISCUSSION: Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.
- 1 October 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (4)
Open AccessPlasma biomarker signatures in patients with rapidly progressive dementia
INTRODUCTION: Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS: Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS: Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p‐tau)217 and p‐tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment–non‐responsive causes of RPD. DISCUSSION: Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.